Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Approves 1st Non-Opioid Pain Medicine in 20 Years
FDA approves first new type of pain medication in 25 years
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill that’s taken every 12 hours after a larger starter dose.
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.
FDA, Axsome and migraine
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Axsome Therapeutics announces FDA approval of Symbravo
Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in
FDA approves new migraine treatment SYMBRAVO
NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue growth over the last twelve months, announced the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO®,
Ozempic receives FDA nod for treating chronic kidney disease
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,
FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes
Doctors already use Ozempic to manage type 2 diabetes and reduce the risk of heart disease in patients with diabetes. This move, as reported by The Times, was based on research sh
Ozempic receives FDA nod for treating chronic kidney disease; experts explain how diabetes drug reduces CKD risk
The US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug, showed a reduced risk of kidney failure. Experts explain how the drug helps.
FDA issues Class I on Lay's potato chips
Chocolate Recall Update As FDA Sets Highest Risk Level for 9 States
A recall which was issued across nine states has now been given the highest risk classification by the federal agency.
FDA reclassifies Lay’s potato chips recall to the highest risk level, warning the chips could cause ‘serious adverse health consequences or death’
The FDA has raised the risk level on a recall of Lay’s potato chips to the highest level, warning the recalled product could cause death. The chips were originally recalled last month for containing undeclared milk.
Put down the bag of chips: FDA issues Class I on Lays potato chips for undeclared allergen
According to the FDA, If consumers have an allergy or sensitivity to milk, they should not consume the product and discard it immediately.
12h
US FDA Identifies Cybersecurity Risks in Certain Patient Monitors
(Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks ...
2d
on MSN
Trump admin's FDA withdraws proposed federal rule to ban menthol cigarettes
Trump's FDA moved to squash a proposed rule to ban menthol cigarettes just one day after the president was sworn in, angering ...
AFP
1h
Vertex Announces FDA Approval of JOURNAVXâ„¢ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Crash at Reagan airport
Los Angeles wildfire updates
Cause of death revealed
Asteroid may hit Earth
Signs education orders
Ex-worker admits to theft
Blames DEI for crash
Michigan priest loses license
Hamas confirms death
Searching for joyriders
'As Tears Go By' singer dies
First spacewalk together
Wildfire erupts in NC
DOJ weighs dropping case?
Accused of sexual misconduct
Hamas frees more hostages
S3 release date revealed
Ebola outbreak in Uganda
2 more victims in indictment
Ground stop amid IT outage
Weekly jobless claims fall
Syria’s transitional pres
Partners w/ US national labs
Day 2 of Senate hearing
Deputy shooting sentence
Nashville bids for franchise
Shiffrin finishes 10th
Senate confirmation hearing
US economy grew 2.3%
DOJ sues to block deal
FDA approves painkiller
Related topics
Trump
Washington
United States
Food and Drug Administration
Journavx
Feedback